Wolfram syndrome and diabetes mellitus in Aotearoa, New Zealand: Phenotype and response to GLP ‐1 receptor agonist therapy

Abstract Aim To describe the clinical characteristics of patients with Wolfram syndrome (WFS) and diabetes mellitus (DM) in Aotearoa, New Zealand. Review of response to therapy in those treated with glucagon‐like peptide‐1 receptor agonists (GLP1RA). Methods This retrospective cohort study describes 7 patients with WFS1 genetic variants (1 patient with WFS‐like syndrome), and DM from 5 New Zealand families (age range 5–33 years, 4 females, 3 males). All are receiving insulin. In 5 patients receiving GLP1RA therapy, we described their pre‐ and post‐treatment biometric parameters, glycaemic control and visual acuity. Results Genetic testing identified compound heterozygous variants in the WFS1 gene (inherited from each parent) in five patients. Another two were heterozygous carriers of a single WFS1 missense variant, one of which was associated with uniparental disomy. Among patients receiving GLP1RA therapy, reductions were seen in HbA1c (mean 11.6 mmol/mol) and total daily insulin dose (mean 0.25 units/kg/day). Conclusions We report genotypic and phenotypic variability in association with clinical features, including age of onset and severity. GLP1RA therapy was associated with improvements in diabetic control. Longer‐term follow‐up is required to monitor for sustained benefit and for progression or improvement in other WFS clinical features.